Induction of complement-dependent and -independent neutralizing antibodies by recombinant-derived human cytomegalovirus gp55-116 (gB)

No abstract is available for this paper.

• Publication year

  1988

• Venue

  Journal of Virology

• Publication date

  1988-09-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1128/jvi.62.9.3309-3318.1988PMID 2841483PMCID PMC253452
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Structural and immunological characterization of the intracellular forms of an abundant 68,000 Mr human cytomegalovirus protein.

  1987cited by this paper
• Epstein-Barr virus glycoprotein homologous to herpes simplex virus gB

  1987cited by this paper
• Antibody response to virus-encoded proteins after cytomegalovirus mononucleosis.

  1987cited by this paper
• Vaccination with recombinant herpes simplex virus glycoproteins: protection against initial and recurrent genital herpes.

  1987cited by this paper
• Mapping of the major glycoprotein gene of human cytomegalovirus.

  1986influential reference
• HTLV-III/LAV-neutralizing antibodies to an E. coli-produced fragment of the virus envelope.

  1986cited by this paper
• Resistance to human respiratory syncytial virus (RSV) infection induced by immunization of cotton rats with a recombinant vaccinia virus expressing the RSV G glycoprotein.

  1986cited by this paper
• Identification of the human cytomegalovirus glycoprotein B gene and induction of neutralizing antibodies via its expression in recombinant vaccinia virus.

  1986influential reference
• Immune responses to isolated human cytomegalovirus envelope proteins

  1986cited by this paper
• T-lymphocyte priming and protection against Friend leukemia by vaccinia-retrovirus env gene recombinant.

  1986cited by this paper
• Characterization of monoclonal antibodies reactive to several biochemically distinct human cytomegalovirus glycoprotein complexes

  1986cited by this paper
• Synthesis and processing of the envelope gp55-116 complex of human cytomegalovirus

  1986cited by this paper
• Vaccinia virus recombinants: expression of VSV genes and protective immunization of mice and cattle.

  1985cited by this paper
• Identification of a 65 000 dalton virion envelope protein of human cytomegalovirus.

  1985cited by this paper
• Viral polypeptides detected by a complement-dependent neutralizing murine monoclonal antibody to human cytomegalovirus

  1985cited by this paper
• Human cytomegalovirus polypeptides stimulate neutralizing antibody in vivo.

  1985cited by this paper
• A murine monoclonal antibody recognising a single glycoprotein within a human cytomegalovirus virion envelope glycoprotein complex

  1985cited by this paper
• Anatomy of the herpes simplex virus 1 strain F glycoprotein B gene: primary sequence and predicted protein structure of the wild type and of monoclonal antibody-resistant mutants

  1985cited by this paper
• Epstein-Barr virus genome may encode a protein showing significant amino acid and predicted secondary structure homology with glycoprotein B of herpes simplex virus 1

  1985cited by this paper
• Glycoproteins Specified by Herpes Simplex Viruses

  1985cited by this paper
• Herpesvirus infections in the acquired immune deficiency syndrome.

  1984cited by this paper
• Murine monoclonal antibody to a single protein neutralizes the infectivity of human cytomegalovirus.

  1984cited by this paper
• Polymorphism of human cytomegalovirus glycoproteins characterized by monoclonal antibodies.

  1984influential reference
• Characterization of monoclonal antibodies and polyclonal immune sera directed against human cytomegalovirus virion proteins.

  1984cited by this paper
• Neutralizing antibodies detect a disulfide-linked glycoprotein complex within the envelope of human cytomegalovirus.

  1984cited by this paper
• Infectious poxvirus vectors have capacity for at least 25 000 base pairs of foreign DNA.

  1983cited by this paper
• Herpes simplex virus type-1 glycoprotein D gene: nucleotide sequence and expression in Escherichia coli.

  1982cited by this paper
• Nonbacterial pneumonia after allogeneic marrow transplantation: a review of ten years' experience.

  1982cited by this paper
• Electrophoretic analysis of polypeptides immune precipitated from cytomegalovirus-infected cell extracts by human sera

  1982cited by this paper
• Conditional expression of the vesicular stomatitis virus glycoprotein gene in Escherichia coli.

  1981cited by this paper
• Use of monoclonal antibody directed against herpes simplex virus glycoproteins to protect mice against acute virus-induced neurological disease

  1981cited by this paper
• Natural history of perinatal cytomegaloviral infection.

  1979cited by this paper
• Human cytomegalovirus: glycoproteins associated with virions and dense bodies

  1976cited by this paper

• Complement-mediated enhancement of SARS-CoV-2 antibody neutralisation potency in vaccinated individuals

  2025cites this paper
• The Interactions of the Complement System with Human Cytomegalovirus

  2024cites this paper
• Direct enhancement of viral neutralising antibody potency by the complement system: a largely forgotten phenomenon

  2024cites this paper
• A temperature-dependent virus-binding assay reveals the presence of neutralizing antibodies in human cytomegalovirus gB vaccine recipients’ sera

  2023cites this paper
• Prenatal Immunization to Prevent Viral Disease Outcomes During Pregnancy and Early Life

  2022cites this paper
• Complement in malaria immunity and vaccines

  2019cites this paper
• Development of novel vaccines against human cytomegalovirus

  2019cites this paper
• Novel trimeric human cytomegalovirus glycoprotein B elicits a high-titer neutralizing antibody response.

  2018cites this paper
• Multiantigenic Modified Vaccinia Virus Ankara Vaccine Vectors To Elicit Potent Humoral and Cellular Immune Reponses against Human Cytomegalovirus in Mice

  2018cites this paper
• Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity.

  2018cites this paper
• Diagnosis of viral central nervous system infections using antipeptide antibody against viral antigen by ELISA.

  2018cites this paper
• Investigating and exploiting the latency-associated expression of the human cytomegalovirus gene US28 in early myeloid lineage cells.

  2017cites this paper
• Positively Selected Sites at HCMV gB Furin Processing Region and Their Effects in Cleavage Efficiency

  2017cites this paper
• Complement enhances in vitro neutralizing potency of antibodies to human cytomegalovirus glycoprotein B (gB) and immune sera induced by gB/MF59 vaccination

  2017cites this paper
• Humoral responses to Cytomegalovirus glycoprotein B vaccine with MF59 adjuvant

  2017cites this paper
• Additive Protection against Congenital Cytomegalovirus Conferred by Combined Glycoprotein B/pp65 Vaccination Using a Lymphocytic Choriomeningitis Virus Vector

  2016cites this paper
• Towards understanding of Human Cytomegalovirus in Glioblastoma

  2016cites this paper
• Structure of HCMV glycoprotein B in the postfusion conformation bound to a neutralizing human antibody

  2015cites this paper
• Human Cytomegalovirus Vaccine Based on the Envelope gH/gL Pentamer Complex

  2014cites this paper
• Vectored co-delivery of human cytomegalovirus gH and gL proteins elicits potent complement-independent neutralizing antibodies.

  2013cites this paper
• Cytomegalovirus Infection in Vascular Diseases and Transplant Rejection

  2012cites this paper
• The Role of Immune Reconstitution in Cytomegalovirus Infection

  2012cites this paper
• Human cytomegalovirus immunity and immune evasion.

  2011cites this paper
• Human Cytomegalovirus Glycoprotein B Genotypes in Chinese Hematopoietic Stem Cell Transplant Recipients

  2011cites this paper
• Analysis of human cytomegalovirus glycoprotein N genotypes in Chinese hematopoietic stem cell transplant recipients

  2010cites this paper
• Monoclonal antibodies

  2010cites this paper
• Cytomegalovirus-specific, high-avidity IgG with neutralizing activity in maternal circulation enriched in the fetal bloodstream.

  2009cites this paper
• Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers.

  2009cites this paper
• Etablierung und Evaluierung eines Mikroneutralisationstests mit Trophoblasten- Primärkulturen zur Abschätzung des HCMV-Transmissionsrisikos bei maternaler Primärinfektion

  2009cites this paper
• Recombinant human monoclonal antibodies to human cytomegalovirus glycoprotein B neutralize virus in a complement-dependent manner.

  2009cites this paper
• Cytomegalovirus Strain Diversity in Seropositive Women

  2008cites this paper
• Cellular and Humoral Immune Responses to Alphavirus Replicon Vaccines Expressing Cytomegalovirus pp65, IE1, and gB Proteins

  2007cites this paper
• Novel therapies for cytomegalovirus disease.

  2007cites this paper
• Development and preclinical evaluation of an alphavirus replicon particle vaccine for cytomegalovirus.

  2007cites this paper
• DNA vaccines expressing glycoprotein complex II antigens gM and gN elicited neutralizing antibodies against multiple human cytomegalovirus (HCMV) isolates.

  2007cites this paper
• Enhancement of neutralizing activity of influenza virus-specific antibodies by serum components.

  2006cites this paper
• The incidence of congenital cytomegalovirus infections in The Netherlands

  2005cites this paper
• Induction by sodium butyrate of cytomegalovirus replication in human endothelial cells

  2005cites this paper
• Alteration of nuclear lamina protein in human fibroblasts infected with cytomegalovirus (HCMV)

  2005cites this paper
• Analysis of human antibody responses to human cytomegalovirus envelope glycoproteins found in two families of disulfide linked glycoprotein complexes designated gC-I and gC-II

  2005cites this paper
• Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism.

  2005cites this paper
• Congenital cytomegalovirus (CMV) infections: hats off to Alabama.

  2003cites this paper
• Congenital Cytomegalovirus Infection: Review of the Epidemiology and Outcome

  2002cites this paper
• Immunogenicity of a recombinant human cytomegalovirus gB vaccine in seronegative toddlers.

  2002cites this paper
• Effect of previous or simultaneous immunization with canarypox expressing cytomegalovirus (CMV) glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV-seronegative adults.

  2002cites this paper
• Strategies to prevent CMV infection in the neonate.

  2002cites this paper
• Longitudinal analysis of human cytomegalovirus glycoprotein B (gB)‐specific and neutralizing antibodies in AIDS patients either with or without cytomegalovirus end‐organ disease

  2001cites this paper
• Lack of association between the kinetics of human cytomegalovirus (HCMV) glycoprotein B (gB)‐specific and neutralizing serum antibodies and development or recovery from HCMV active infection in patients undergoing allogeneic stem cell transplant

  2001cites this paper
• Vaccination of Seropositive Subjects with CHIRON CMV gB Subunit Vaccine Combined with MF59 Adjuvant for Production of CMV Immune Globulin

  2000cites this paper
• Antibodies to the Major Linear Neutralizing Domains of Cytomegalovirus Glycoprotein B Among Natural Seropositives and CMV Subunit Vaccine Recipients

  2000cites this paper
• Characterization of a Panel of Insertion Mutants in Human Cytomegalovirus Glycoprotein B

  2000cites this paper
• Early neutralizing and glycoprotein B (gB)-specific antibody responses to human cytomegalovirus (HCMV) in immunocompetent individuals with distinct clinical presentations of primary HCMV infection.

  2000cites this paper
• Little role of anti-gB antibodies in neutralizing activity of patient's sera with human cytomegalovirus (HCMV) infection.

  2000cites this paper
• Effects of antigen dose and immunization regimens on antibody responses to a cytomegalovirus glycoprotein B subunit vaccine.

  1999cites this paper
• Functional antibody response to human cytomegalovirus in immunocompetent and HIV-1 infected individuals with antibodies that inhibit virus penetration into cells and intercellular transmission of viral infection.

  1999cites this paper
• Identification of human cytomegalovirus variants by analysis of single strand conformation polymorphism and DNA sequencing of the envelope glycoprotein B gene region-distribution frequency in liver transplant recipients.

  1999cites this paper
• Herpesvirus vaccines. Development, controversies, and applications.

  1999cites this paper
• The selected lymphocyte antibody method : a novel approach for the generation and genetic analysis of human cytomegalovirus (HCMV) neutralizing monoclonal IgG antibodies

  1999cites this paper
• Induction of Neutralizing Antibody against Human Cytomegalovirus (HCMV) with DNA‐Mediated Immunization of HCMV Glycoprotein B in Mice

  1999cites this paper
• Molecular pathogenesis of human cytomegalovirus infection

  1999cites this paper
• Antibody response to human cytomegalovirus (HCMV) glycoprotein B (gB) in AIDS patients with HCMV end‐organ disease

  1998cites this paper
• Humoral immune response to functional regions of human cytomegalovirus glycoprotein B

  1997cites this paper
• Functional analysis of the transmembrane anchor region of bovine herpesvirus 1 glycoprotein gB.

  1997cites this paper
• Glycoprotein H-related complexes of human cytomegalovirus: identification of a third protein in the gCIII complex

  1997cites this paper
• Neutralization of cytomegalovirus virions: the role of complement.

  1997cites this paper
• Recognition of human cytomegalovirus gene products by HCMV-specific cytotoxic T cells.

  1996cites this paper
• Murine cytomegalovirus inactivated by sodium periodate is innocuous and immunogenic in mice and protects them against death and infection.

  1996cites this paper
• Developments in childhood immunization.

  1996cites this paper
• Preclinical evaluation of an ALVAC (canarypox)--human cytomegalovirus glycoprotein B vaccine candidate.

  1995cites this paper
• Human cytomegalovirus neutralizing antibody-resistant phenotype is associated with reduced expression of glycoprotein H

  1995cites this paper
• Constitutive expression of human cytomegalovirus glycoprotein B (gpUL55) with mutagenized carboxy-terminal hydrophobic domains.

  1995cites this paper
• Antiviral antibody responses and intrauterine transmission after primary maternal cytomegalovirus infection.

  1995cites this paper
• Formulation of an immunogenic human cytomegalovirus vaccine: responses in mice.

  1995cites this paper
• Infection in the Organ Transplant Recipient

  1994cites this paper
• Development and Clinical Status of Cytomegalovirus Vaccines

  1994cites this paper
• Human cytomegalovirus structural proteins.

  1994cites this paper
• Review article Human cytomegalovirus structural proteins

  1994cites this paper
• Ontogeny of glycoprotein gB‐specific antibody and neutralizing activity during natural cytomegalovirus infection

  1994cites this paper
• Function of glycoprotein B homologues of the family herpesviridae.

  1994cites this paper
• Function of human cytomegalovirus glycoprotein B: syncytium formation in cells constitutively expressing gB is blocked by virus-neutralizing antibodies.

  1994cites this paper
• Murine cytotoxic T cell response specific for human cytomegalovirus glycoprotein B (gB) induced by adenovirus and vaccinia virus recombinants expressing gB.

  1993cites this paper
• Detection of neutralizing antibodies against human cytomegalovirus: Influence of strain variation

  1993cites this paper
• Sequence variation within neutralizing epitopes of the envelope glycoprotein B of human cytomegalovirus: comparison of isolates from renal transplant recipients and AIDS patients.

  1993cites this paper
• Vaccine Strategies for the Prevention of Cytomegalovirus Disease

  1993cites this paper
• Proteins of Human Cytomegalovirus that Elicit Humoral Immunity

  1993cites this paper
• Glycoprotein B of human cytomegalovirus promotes virion penetration into cells, transmission of infection from cell to cell, and fusion of infected cells.

  1993cites this paper
• Development of subunit preparations of cytomegalovirus antigen by aqueous extraction for immunization against cytomegalovirus infection.

  1993cites this paper
• Assembly of conformation-dependent neutralizing domains on glycoprotein B of human cytomegalovirus.

  1992cites this paper
• The amino terminus of human cytomegalovirus glycoprotein B contains epitopes that vary among strains.

  1992cites this paper
• A combination of human cytomegalovirus (HCMV)-specific murine monoclonal antibodies exhibits synergistic antiviral activity in vitro.

  1992cites this paper
• Use of the polymerase chain reaction to analyse sequence variation within a major neutralizing epitope of glycoprotein B (gp58) in clinical isolates of human cytomegalovirus.

  1991cites this paper
• The cloning and expression of herpes simplex virus type 1 glycoprotein c in vaccinia virus.

  1991cites this paper
• Class I MHC-restricted cytotoxic T lymphocyte recognition of cells infected with human cytomegalovirus does not require endogenous viral gene expression.

  1991cites this paper
• A recombinant subunit vaccine approach to HCMV vaccine development.

  1991cites this paper
• Mapping of serologically relevant regions of human cytomegalovirus phosphoprotein pp150 using synthetic peptides.

  1991cites this paper
• High expression of human cytomegalovirus (HCMV)-gB protein in cells infected with a vaccinia-gB recombinant: the importance of the gB protein in HCMV immunity.

  1991cites this paper
• Distribution of linear antigenic sites on glycoprotein gp55 of human cytomegalovirus

  1991cites this paper
• The gp116 of the gp58/116 complex of human cytomegalovirus represents the amino-terminal part of the precursor molecule and contains a neutralizing epitope.

  1990cites this paper
• An adenovirus recombinant that expresses the human cytomegalovirus major envelope glycoprotein and induces neutralizing antibodies.

  1990cites this paper
• Structure and composition of a family of human cytomegalovirus glycoprotein complexes designated gC-I (gB).

  1990cites this paper